Belumosudil in diffuse cutaneous systemic sclerosis: a randomized, double-blind, open-label extension, placebo-controlled, phase 2 study.

Rheumatology (Oxford) · 2025 · PMC12212915 · PMID 40088930

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

HA, PNIIIP and TIMP-1) exhibited a decreasing trend in the treated groups compared with that in the placebo group at baseline, week 4, week 8 and week 24 ( Supplementary Fig.

also in 47,180 other papers

a clear trendno p-value reported

PFT parameters, including FVC in the overall population and in patients with underlying ILD, did not exhibit a clear trend due to the small sample size ILD population.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.